BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 1601333)

  • 1. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
    Bhalla K; Holladay C; Lutzky J; Ibrado AM; Bullock G; Jasiok M; Singh S
    Gynecol Oncol; 1992 Apr; 45(1):32-9. PubMed ID: 1601333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
    Lech-Maranda E; Korycka A; Robak T
    Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.
    Bhalla K; MacLaughlin W; Cole J; Arlin Z; Baker M; Graham G; Grant S
    Blood; 1987 Aug; 70(2):568-71. PubMed ID: 3607288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
    Csoka K; Liliemark J; Larsson R; Nygren P
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):47-53. PubMed ID: 7481845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed addition of deoxycytidine protects normal CD34+ cells against cytotoxicity of gemcitabine without compromising its activity against human leukemic cells.
    Tiefenthaler M; Hohla F; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
    Stem Cells; 2003; 21(3):266-71. PubMed ID: 12743321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
    Bouffard DY; Momparler LF; Momparler RL
    Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
    Vrana JA; Kramer LB; Saunders AM; Zhang XF; Dent P; Povirk LF; Grant S
    Biochem Pharmacol; 1999 Jul; 58(1):121-31. PubMed ID: 10403525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
    van Bree C; Castro Kreder N; Loves WJ; Franken NA; Peters GJ; Haveman J
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):237-44. PubMed ID: 12182997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM; Giaccone G; van Moorsel CJ; Mauritz R; Noordhuis P; Pinedo HM; Peters GJ
    Eur J Cancer; 2000 Oct; 36(15):1974-83. PubMed ID: 11000580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
    Graziadei I; Kelly T; Schirmer M; Geisen FH; Vogel W; Konwalinka G
    J Hepatol; 1998 Mar; 28(3):504-9. PubMed ID: 9551690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
    Ross DD; Cuddy DP
    Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
    Tiefenthaler M; Hohla F; Irschick E; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
    Immunobiology; 2003; 207(2):149-57. PubMed ID: 12675273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.